FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 31, Pages 6987
Publisher
Baishideng Publishing Group Inc.
Online
2016-08-15
DOI
10.3748/wjg.v22.i31.6987
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
- (2016) Srinivasa P Pothula et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers
- (2016) Eugene J. Koay et al. CANCER LETTERS
- Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib
- (2016) Ganji Purnachandra Nagaraju et al. EUROPEAN JOURNAL OF CANCER
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
- (2016) Andrew H. Ko et al. PANCREAS
- MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulatingPTENandPDCD4
- (2016) Xueju Wei et al. Cancer Medicine
- T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
- (2015) Ingunn M. Stromnes et al. CANCER CELL
- RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics
- (2015) Myron G. Best et al. CANCER CELL
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
- (2015) A. H. Ko et al. CLINICAL CANCER RESEARCH
- The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
- (2015) F. Vena et al. CLINICAL CANCER RESEARCH
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
- (2015) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
- (2015) L. A. Chantrill et al. CLINICAL CANCER RESEARCH
- Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trial
- (2015) M. Sinn et al. EUROPEAN JOURNAL OF CANCER
- High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis
- (2015) Cindy Neuzillet et al. HISTOPATHOLOGY
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
- (2015) Michela Capello et al. JNCI-Journal of the National Cancer Institute
- TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas
- (2015) Mie Grunnet et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
- (2015) Vanja Vaccaro WORLD JOURNAL OF GASTROENTEROLOGY
- MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
- (2015) Liza C. Villaruz et al. Clinical Epigenetics
- Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
- (2015) Michela Capello et al. JNCI-Journal of the National Cancer Institute
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
- (2014) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
- (2014) E Van Cutsem et al. BRITISH JOURNAL OF CANCER
- Pancreatic Cancer Stroma: Friend or Foe?
- (2014) Jesse Gore et al. CANCER CELL
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell–endothelial cell interactions: antiangiogenic implications in pancreatic cancer
- (2014) Mishaal B. Patel et al. CARCINOGENESIS
- Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression
- (2014) Thorsten Fuereder et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6
- (2014) Xiaolan Zhu et al. INTERNATIONAL JOURNAL OF CANCER
- Stromal MicroRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer
- (2014) Timothy R. Donahue et al. JOURNAL OF SURGICAL ONCOLOGY
- Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development
- (2014) Jared R Mayers et al. NATURE MEDICINE
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan
- (2014) Jakob V. Schou et al. PLoS One
- Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
- (2014) Mogens K. Boisen et al. PLoS One
- SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
- (2014) Neil Desai et al. Translational Oncology
- Personalising pancreas cancer treatment: When tissue is the issue
- (2014) Katrin M Sjoquist WORLD JOURNAL OF GASTROENTEROLOGY
- Recent studies of 5-fluorouracil resistance in pancreatic cancer
- (2014) Wei-Bin Wang WORLD JOURNAL OF GASTROENTEROLOGY
- Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer
- (2014) Ingrid Garajová et al. Biomed Research International
- Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
- (2013) Jun-Eul Hwang et al. BMC CANCER
- Treatment of HER2-positive breast cancer
- (2013) Maria Cristina Figueroa-Magalhães et al. BREAST
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
- (2013) R Alvarez et al. BRITISH JOURNAL OF CANCER
- Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
- (2013) A. Avan et al. CANCER RESEARCH
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- (2013) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
- (2013) Philippe Rougier et al. EUROPEAN JOURNAL OF CANCER
- MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression
- (2013) Adam E. Frampton et al. GASTROENTEROLOGY
- Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer:XPD-Lys751Glnpolymorphism strikes back
- (2013) Amir Avan et al. INTERNATIONAL JOURNAL OF CANCER
- miRNA27a Is a Biomarker for Predicting Chemosensitivity and Prognosis in Metastatic or Recurrent Gastric Cancer
- (2013) Dingzhi Huang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- nab-Paclitaxel mechanisms of action and delivery
- (2013) Denise A. Yardley JOURNAL OF CONTROLLED RELEASE
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase
- (2013) Yunfei Zhou et al. Molecular Oncology
- Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
- (2013) J.B. Kjersem et al. Molecular Oncology
- High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer
- (2013) Mads H. Rasmussen et al. Molecular Oncology
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- (2013) Luc Friboulet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers
- (2013) Christina H. Wei et al. PANCREAS
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
- (2013) Hemchandra Mahaseth et al. PANCREAS
- CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
- (2013) A. Neesse et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
- (2013) C Hage et al. Cell Death & Disease
- The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
- (2013) Thierry Conroy et al. Current Oncology Reports
- The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
- (2012) S. Caponi et al. ANNALS OF ONCOLOGY
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- (2012) A. Gonçalves et al. ANNALS OF ONCOLOGY
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
- (2012) J Harder et al. BRITISH JOURNAL OF CANCER
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- The Pancreas Cancer Microenvironment
- (2012) C. Feig et al. CLINICAL CANCER RESEARCH
- Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
- (2012) Maha Elnaggar et al. CURRENT PHARMACEUTICAL DESIGN
- Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
- (2012) Chen Sun WORLD JOURNAL OF GASTROENTEROLOGY
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer
- (2011) Troels K. Bergmann et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
- (2011) Chenwei Li et al. GASTROENTEROLOGY
- Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil
- (2011) Hayato Fujita INTERNATIONAL JOURNAL OF ONCOLOGY
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy
- (2011) Elisa Giovannetti et al. PHARMACOGENOMICS
- MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
- (2010) Elisa Giovannetti et al. CANCER RESEARCH
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan
- (2010) V Boni et al. PHARMACOGENOMICS JOURNAL
- Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer
- (2010) Jin-Hyeok Hwang et al. PLoS One
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
- (2009) D. R. Cochrane et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
- Potential of Spice-Derived Phytochemicals for Cancer Prevention
- (2008) Bharat Aggarwal et al. PLANTA MEDICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started